Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
111.77
-2.70 (-2.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biontech Se ADR
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
64
65
Next >
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
November 10, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Exposures
COVID-19
Product Safety
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
November 10, 2022
Learn more about Organicell Regenerative Medicine, Inc.from this latest report.
Via
TheNewswire.com
Exposures
COVID-19
Product Safety
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
November 10, 2022
Via
Benzinga
This COVID-19 Vaccine Stock Has More to Offer
November 10, 2022
The vaccine revenue was nice, but it's time to look ahead.
Via
The Motley Fool
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
November 10, 2022
From
BioNTech SE
Via
GlobeNewswire
BioNTech SE (BNTX) Q3 2022 Earnings Call Transcript
November 07, 2022
BNTX earnings call for the period ending September 30, 2022.
Via
The Motley Fool
2 Top Healthcare Stocks to Buy Right Now
November 10, 2022
These two dividend stocks offer 3%-plus dividend yields that are secure.
Via
The Motley Fool
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
November 10, 2022
During the peak of the deadly COVID-19 pandemic, one novel therapeutic that seems to have played an important role in helping save lives was Organicell Regenerative Medicine Inc.’s (OTCMKTS:...
Via
Benzinga
Return To Office: Pfizer To Enforce 2-3 Days In Office Starting January
November 09, 2022
Pfizer Inc's (NYSE: PFE) CEO Albert Bourla said the U.S. employees would have to return to their workplaces two to three days a week starting in January.
Via
Benzinga
The 7 Best Pharma Stocks to Buy Now
November 08, 2022
Investors searching for gains in the current market storm should consider taking a position in some of the best pharma stocks.
Via
InvestorPlace
Got $2,000? 2 Fantastic Stocks to Buy No Matter What the Market Does Next
November 08, 2022
These stocks both have non-cyclical businesses that can drive growth in a wide variety of markets.
Via
The Motley Fool
BioNTech Takes A Hit Despite Doubling Profit Views, Raising 2022 Outlook
November 07, 2022
BioNTech doubled profit expectations in the third quarter and raised its outlook.
Via
Investor's Business Daily
Meta Goes Twitter Way With Layoffs, Twitter Might Want Some People Back After Firing Them, Coal Miners Terminate $6B Combination Discussions: Top Stories Monday, Nov. 07
November 07, 2022
Wall Street Journal
Via
Benzinga
BioNTech Posts About 50% Drop In Q3 Sales and Profits Amid Falling Demand For COVID-19 Shots
November 07, 2022
Via
Benzinga
Risk Appetites Survive China Keeping Zero COVID Policy
November 07, 2022
Chinese officials denied plans to end the zero-COVID policy and after a brief wobble, risk assets have traded better. Asia Pacific equities rallied, led by Hong Kong and mainland stocks that trade in...
Via
Talk Markets
Recap: BioNTech Q3 Earnings
November 07, 2022
BioNTech (NASDAQ:BNTX) reported its Q3 earnings results on Monday, November 7, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings BioNTech beat estimated earnings by...
Via
Benzinga
BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
November 07, 2022
From
BioNTech SE
Via
GlobeNewswire
Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex
November 05, 2022
Deals, financings, trials and approvals in Chinese biotech/biopharma this week.
Via
Talk Markets
Did Vaccine Stocks Just Get Their Last Boost?
November 04, 2022
Some positive news sent their share prices higher, but biotech companies will need to find other ways to make money.
Via
The Motley Fool
This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters
November 04, 2022
Pfizer and BioNTech tested their updated Covid booster against the original shot.
Via
Investor's Business Daily
BioNTech's COVID-19 Vaccine Becomes First Foreign Shot To Be Available In Chinese Market
November 04, 2022
German Chancellor Olaf Scholz agreed to allow expatriates in China to use BioNTech SE (NASDAQ: BNTX) made COVID-19 vaccine. BioNTech would be the first non-Chinese coronavirus vaccine in China, as...
Via
Benzinga
Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity
November 04, 2022
Via
Benzinga
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
November 04, 2022
From
BioNTech SE
Via
GlobeNewswire
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
November 04, 2022
From
Pfizer Inc.
Via
Business Wire
BioNTech Shares Up On Hope For Combined Flu, Covid Shot
November 03, 2022
The shot will combine Pfizer's quadrivalent flu shot with the bivalent Covid booster.
Via
Investor's Business Daily
Pfizer, BioNTech Launch Omicron-Adapted COVID Shot-Flu Combination Vaccine Study
November 03, 2022
Via
Benzinga
Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today
October 28, 2022
The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster.
Via
The Motley Fool
A New BioTech Research Race Is Focused On Improving Life For MS Patients
October 27, 2022
When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is...
Via
Benzinga
Is BioNTech a Good Long-Term Buy?
October 27, 2022
BioNTech has a burgeoning oncology portfolio up its sleeve.
Via
The Motley Fool
Are Pfizer and Moderna Stocks Buys With a Potential COVID Surge Coming?
October 26, 2022
There's still considerable near-term uncertainty for both of these vaccine makers.
Via
The Motley Fool
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
64
65
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.